ASTRO issues guide on accelerated breast radiotherapy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 8
Volume 18
Issue 8

Patient selection criteria and best practices for the use of accelerated partial breast irradiation, outside of a clinical trial, are covered by the American Society of Radiation Oncology in a consensus statement.

Patient selection criteria and best practices for the use of accelerated partial breast irradiation, outside of a clinical trial, are covered by the American Society of Radiation Oncology in a consensus statement. APBI has several benefits, including a decreased overall treatment time and a decrease in the radiation delivered to healthy tissue and adjacent organs, but its long-term safety and effectiveness, compared with whole-breast irradiation, are not yet known, according to the ASTRO Task Force. As results of randomized trials comparing APBI with WBI will not be available for many years, guidance for use of APBI is needed (Int J Radiat Oncol Biol Phys 74:987-1001, 2009).

The consensus statement highlights information on:

• Which patients may be considered for APBI
• What constitutes proper informed consent for APBI
• Which diagnostic imaging tests are necessary
• How to integrate APBI with surgical and chemotherapy treatment
• How the various techniques for APBI compare with one another.

Recent Videos
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
5 experts are featured in this series
4 experts in this video
4 experts in this video
4 experts in this video
5 experts are featured in this series
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Related Content